Results 91 to 100 of about 15,616 (165)

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. [PDF]

J Hematol
Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S.   +4 more
europepmc   +1 more source

Characterization and management of serpentine supravenous reaction: A nine-patient case series. [PDF]

JAAD Case Rep
Lu K, Arkema G, Cohen JN, Francois RA, Ramseier JY, Dobry AS.   +5 more
europepmc   +1 more source

A Computational Investigation of the ¹⁵N Chemical Shift Behavior of <i>Strychnos</i> Alkaloids. [PDF]

Int J Mol Sci
Semenov VA, Krivdin LB, Martin GE.
europepmc   +1 more source

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme. [PDF]

Commun Med (Lond)
Angom RS, Rachamala HK, Nakka NMR, Madamsetty VS, Suarez-Meade P, Fernandez-Gil BI, Kulkarni T, Weil RM, Dutta S, Wang E, Bhattacharya S, Pal K, Quinones-Hinojosa A, Mukhopadhyay D.   +13 more
europepmc   +1 more source

Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations. [PDF]

CPT Pharmacometrics Syst Pharmacol
Chen J, Wada R, Zhang N, Graupner V, Morris S, Hu Y, Zhang W, Kassir N, Wu B, Chan P.   +9 more
europepmc   +1 more source

Modulation of the cytoskeleton for cancer therapy. [PDF]

Front Cell Dev Biol
Matov A.
europepmc   +1 more source

The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study. [PDF]

Transl Breast Cancer Res
Wang X, Yang T, Zhang J, Yang J, Gong R, Liu S, Xue Y.   +6 more
europepmc   +1 more source

Combination Therapy, Drug Interactions, and Survival Outcomes in Metastatic Breast Cancer: A Pooled Analysis of Phase II Trials. [PDF]

Clin Med Insights Oncol
Azam F, Momtaz T, Islam F, Rahman KF, Shobnam S, Paul P, Alam MJ.   +6 more
europepmc   +1 more source

Comparison of the effects of different types of treatment protocols on the median and overall survival rates of non-small cell lung cancer patients: A real-world retrospective study. [PDF]

PLoS One
Siahmansur TJ.
europepmc   +1 more source

Proteasome Inhibitor-Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines. [PDF]

Vet Comp Oncol
Chijiwa A, Inanaga S, Osaki T, Igase M, Mizuno T.   +4 more
europepmc   +1 more source